Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vir Biotechnology, Inc. - Common Stock (NQ:VIR)

5.940 -0.090 (-1.49%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vir Biotechnology, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
News headline image
Vir Biotechnology to Host 2024 Annual Meeting of Stockholders
From Vir Biotechnology, Inc.
Via Business Wire
News headline image
Multiple Abstracts Highlighting Vir Biotechnology’s Latest Hepatitis Delta & B Data Accepted for Presentation at the EASL Congress 2024
From Vir Biotechnology, Inc.
Via Business Wire
News headline image
Vir Biotechnology Announces SOLSTICE Data to be Featured as an Oral Presentation at the European Association for the Study of the Liver (EASL) Congress 2024
From Vir Biotechnology, Inc.
Via Business Wire
News headline image
Deep Dive Into Vir Biotechnology Stock: Analyst Perspectives (6 Ratings) ↗
 
Via Benzinga
News headline image
Assessing Vir Biotechnology: Insights From 5 Financial Analysts ↗
 
Via Benzinga
News headline image
VIR Stock Earnings: Vir Biotechnology Beats EPS for Q1 2024 ↗
VIR stock results show that Vir Biotechnology beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
News headline image
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2024 Financial Results
From Vir Biotechnology, Inc.
Via Business Wire
News headline image
Vir Biotechnology to Participate in the BofA Securities Healthcare Conference 2024
From Vir Biotechnology, Inc.
Via Business Wire
News headline image
Vir Biotechnology Announces Nomination of Norbert Bischofberger, Ph.D. and Ramy Farid, Ph.D. to its Board of Directors
From Vir Biotechnology, Inc.
Via Business Wire
News headline image
Recap: Vir Biotechnology Q4 Earnings ↗
 
Via Benzinga
News headline image
Earnings Outlook For Vir Biotechnology ↗
 
Via Benzinga
News headline image
JP Morgan Downgrades Vir Biotechnology: Here's What You Need To Know ↗
 
Via Benzinga
News headline image
Vir Biotechnology to Provide Business Update and Report First Quarter 2024 Financial Results on May 2, 2024
From Vir Biotechnology, Inc.
Via Business Wire
News headline image
From Six Figures to Seven: 3 Biotech Stocks Set to Make Millionaires ↗
These biotech stocks to buy offer a gateway to long-term gains, on the back of groundbreaking healthcare innovations. 
Via InvestorPlace
News headline image
Billionaire’s Biotech Bets: 3 Stocks Dominating Bill Gates’ Portfolio ↗
One of the primary features of Bill Gates biotech stocks is they are all working towards a cure for HIV and related illnesses. 
Via InvestorPlace
News headline image
Vir Biotechnology Completes Enrollment of Phase 2 Chronic Hepatitis Delta SOLSTICE Trial Ahead of Schedule
From Vir Biotechnology, Inc.
Via Business Wire
News headline image
3 Highly Rated Biotech Stocks to Buy for 300% Gains ↗
Biotech stocks like those discussed here have the potential to produce 300% returns and benefit from high analyst ratings. 
Via InvestorPlace
News headline image
Why MercadoLibre Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗
Shares of MercadoLibre, Inc. (NASDAQ: MELI) fell sharply during Friday’s session after the company reported fourth-quarter financial results. 
Via Benzinga
News headline image
Carvana Posts Q4 Results, Joins LegalZoom.com, Comfort Systems And Other Big Stocks Moving Higher On Friday ↗
U.S. stocks were mostly higher, with the Dow Jones index gaining more than 100 points on Friday. 
Via Benzinga
Topics Stocks
News headline image
Vir Biotechnology to Participate in Upcoming Investor Healthcare Conferences
From Vir Biotechnology, Inc.
Via Business Wire
News headline image
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
From Vir Biotechnology, Inc.
Via Business Wire
News headline image
Vir Biotechnology Announces Dr. Phil Pang Will Step Down as Chief Medical Officer
From Vir Biotechnology, Inc.
Via Business Wire
News headline image
3 Hidden-Gem Biotech Stocks Ready to Ride a Massive Market Wave ↗
Explore hidden-gem biotech stocks set for growth in a booming market. Uncover top picks ready to redefine healthcare innovation. 
Via InvestorPlace
News headline image
Earnings Scheduled For February 22, 2024 ↗
Companies Reporting Before The Bell • Indivior (NASDAQ:INDV) is likely to report quarterly earnings at $0.28 per share on revenue of $260.00 million. 
Via Benzinga
News headline image
Vir Biotechnology to Provide Business Update and Report Fourth Quarter 2023 Financial Results on February 22, 2024
From Vir Biotechnology, Inc.
Via Business Wire
News headline image
HC Wainwright & Co. Maintains Buy Rating for Vir Biotechnology: Here's What You Need To Know ↗
 
Via Benzinga
News headline image
COVAX Global Initiative For COVID-19 Vaccines Comes To An End Amid Shift To Regular Programs ↗
COVAX, the multilateral mechanism for equitable global access to COVID-19 vaccines launched in 2020, will close on 31 December 2023.&n 
Via Benzinga
News headline image
Vir Biotechnology Announces Strategic Steps to Reduce Operating Expenses and Focus Investment on Areas with Highest Potential for Value Creation
From Vir Biotechnology, Inc.
Via Business Wire
News headline image
Vir Biotechnology to Present at J.P. Morgan 2024 42nd Annual Healthcare Conference
From Vir Biotechnology, Inc.
Via Business Wire
News headline image
7 Small-Cap Stocks to Buy BEFORE the Year-End Rally ↗
explore and wager on these top small-cap stocks to buy, poised for significant gains in today's dynamic global economy 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.